The phrase "against nada" is not standard or widely recognized in written English.
It may be used informally to imply opposition to nothing or a lack of resistance, but it is not commonly accepted in formal writing.
Example: "In the debate, he argued that we should not be against nada, as it implies we are opposing nothing."
Alternatives: "against nothing" or "opposed to zero".
(a) Plotting of MFIs relative percentage of spotted human proteins tested against NadA at 150 nM and (b) 1 μM.
Persistence of the immune responses in this study were also investigated at 40 months of age [ 26], and were consistent with the previous study [ 25]; 36 % had titers ≥4 against fHbp, 100%% against NadA, 14 % against NZ OMV, and 79 % against NHBA after 4CMenB vaccination 2 years earlier.
The meningococcal antigen typing system (MATS) uses polyclonal antibodies against fHbp, NadA, and NHBA in an ELISA to quantify the expression and amounts of these individual antigens, which cross-react with the corresponding antigen used in the vaccine.
At least 99%% of infants had hSBA titers of ≥5 against fHbp and NadA 1 month after the primary series completion, irrespective of the schedule.
In the cohort who received 4CMenB, 74 100 % achieved hSBA titers ≥4 against the fHbp, NadA, and PorA 1.4 indicator strains after the second dose and 85 95 % after the third dose.
As reported by Gossger et al. [ 27], immunogenicity against the fHbp, NadA, and NZ OMV test strains produced by vaccination at 2, 4, and 6 months was not substantially different from vaccination at 2, 3, and 4 months.
Sera were tested against the fHbp, NadA, and PorA 1.4 indicator strains with 91 100%% achieving hSBA titers ≥4 after the second 4CMenB dose, with similar immunogenicity (range 92 100%%) after the third 4CMenB dose.
In an unbiased approach, the complete library was expressed and NadA screened against it.
The investigators, Vesikari et al. [ 28], reported that 84 100%% of infants had hSBA titers ≥5 against the vaccine antigens (fHbp, NadA, NHBA, and NZ OMV) after the three-dose primary series at 7 months of age (Fig. 2a).
The evidence in the report against CHIP is: zero, zilch and nada.
NadA and NHBA induce the production of bactericidal antibodies against N. meningitidis serogroup B strains.
